Cell and gene therapies (CGT) offer immense potential for healthcare – opening up countless possibilities for saving and improving lives, which were previously unavailable through existing
In May, the UK Life Sciences Council, a biannual meeting between ministers and global life sciences industry leaders, met to discuss the sector’s economic potential
Industry stakeholders have moved beyond considering patients as clinical trial “subjects”, and instead recognise the tremendous value of viewing those most impacted by a disease as partners
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
